Wenger Vieli advised Swiss AI company Modulos on all Swiss legal and tax matters concerning its CHF 8.7 million pre-Series A financing round. The context The proceeds from the financing round will be directed toward scaling-up
Tags :Pascal Honold
Private equity firm Ardian completed the acquisition of a majority stake in the Dovida Group – formerly Home Instead. UBS Switzerland acted as mandated lead arranger, agent, security agent and original lender on the transaction. In
In line with its rotation model of reorganising the management team every 1.5 years, Wenger Vieli appoints a new management trio, effective 1 July 2025. Bruno Bächli becomes the firm’s new Managing Partner, succeeding Pascal Honold,
Niederer Kraft Frey (NKF) advised Yttrium, a technology investor, on its Series B investment in Embotech, a provider of autonomous driving solutions, advised by Walder Wyss. Other investors in this funding round included Emerald Technology,
Wenger Vieli acted as Swiss legal advisor to NLS Pharmaceutics on all Swiss legal matters in connection with the direct offering and concurrent private placement transaction with certain investors to issue 806,452 of common shares and 806,452
Wenger Vieli, a prominent law firm with a history of dynamic leadership changes every 1.5 years, has announced the appointment of Pascal Honold as the new Managing Partner, effective January 1, 2024. Honold has extensive expertise in the
Wenger Vieli acted as the legal advisor to the sellers of Seervision, a Swiss company specializing in AI-driven camera automation solutions, in its acquisition by QSC. The partnership marks a significant milestone for Seervision, opening
NLS Pharmaceutics, a Swiss clinical-stage biopharmaceutical company, has entered into a definitive agreement with BVF PARTNERS to raise aggregate gross proceeds of up to USD 30.0 million in a two-tranche private placement. The net proceeds will
As we have informed last 3 November 2022 here, Wenger Vieli has also acted as legal and tax advisor to ETH Zurich spin-off LatticeFlow on closing of its USD 12m Series A financing round. The round was
Wenger Vieli has advised NLS Pharmaceutics on a USD 4m private placement and conversion of existing short-term notes of USD 1.53m. NLS Pharmaceutics is a Swiss clinical-stage biopharmaceutical company focused on the discovery and development
